{"classes":[{"categories":[{"measurements":[{"comment":"The median time to treatment failure and the upper and lower confidence limits were not reached.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"}],"units":"Participants"}],"description":"Time to treatment failure is defined to be the time from registration to the date at which the patient is removed from treatment due to progression, adverse events, or refusal. The distribution of time to treatment failure will be estimated using the method of Kaplan-Meier.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with symptomatic untreated low grade NHL will be treated according to a 28 day schedule for up to a maximum of 12 consecutive cycles:\n\n375 mg/m\\^2 Rituximab IV on day 1. 20 mg Lenalidomide taken orally on days 1-21. 250 mg/m\\^2 Cyclophosphamide orally on days 1, 8, 15. 40 mg Dexamethasone orally on days 1, 8, 15, 22.","id":"OG000","title":"Treatment"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Up to 1 year from registration.","title":"Time to Treatment Failure","type":"SECONDARY","unitOfMeasure":"months"}